947547-39-9Relevant academic research and scientific papers
Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: Novel CYP17 inhibitors for the treatment of prostate cancer
Pinto-Bazurco Mendieta, Mariano A. E.,Negri, Matthias,Jagusch, Carsten,Müller-Vieira, Ursula,Lauterbach, Thomas,Hartmann, Rolf W.
supporting information; experimental part, p. 5009 - 5018 (2009/07/04)
Abiraterone, a steroidal cytochrome P450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer. Since steroidal compounds often show side
Novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1: Templates for design
Allan, Gillian M.,Vicker, Nigel,Lawrence, Harshani R.,Tutill, Helena J.,Day, Joanna M.,Huchet, Marion,Ferrandis, Eric,Reed, Michael J.,Purohit, Atul,Potter, Barry V.L.
, p. 4438 - 4456 (2008/09/21)
The 17β-hydroxysteroid dehydrogenases (17β-HSDs) catalyze the interconversion between the oxidized and reduced forms of androgens and estrogens at the 17 position. The 17β-HSD type 1 enzyme (17β-HSD1) catalyzes the reduction of estrone (E1) to estradiol a
